(S)-3-amino-3-(2,4-dimethoxyphenyl)propanoic acid | 951174-49-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-amino-3-(2,4-dimethoxyphenyl)propanoic acid
• 英文别名: (3S)-3-azaniumyl-3-(2,4-dimethoxyphenyl)propanoate
• CAS: 951174-49-5
• 化学式: C₁₁H₁₅NO₄
• 分子量: 225.244
• InChiKey: RYDBREOLOYHYQB-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  tert-butyl (S)-3-amino-3-(2,4-dimethoxyphenyl)propanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以99%的产率得到(S)-3-amino-3-(2,4-dimethoxyphenyl)propanoic acid
  参考文献：
  名称：

  平行合成手性β-氨基酸

  摘要：

  使用高手性锂N-苄基-N-（α-甲基苄基）酰胺的共轭加成，完成了对映体纯度高的30个β-氨基酸阵列的平行不对称合成。该协议的实验简单性和高度实用性通过高15种α，β-不饱和酯的高效平行转化为相应β-氨基酸的对映体系列以高总收率和选择性进行了证明，且每个步骤的纯化步骤最少反应方案。

  DOI：

  10.1016/j.tetasy.2007.06.008

文献信息

• Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them
  申请人：——

  公开号：US20030125565A1

  公开（公告）日：2003-07-03

  The present invention relates to novel imidazolidine derivatives of the formula I, 1 in which B, E, W, Z, R, R 0 , R 2 , R 3 , e and h have the meanings indicated in the application. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use in the therapy and prophylaxis of the disease states mentioned and pharmaceutical preparations which contain compounds of the formula I.

  本发明涉及公式I的新型咪唑啉衍生物，其中B、E、W、Z、R、R0、R2、R3、e和h在申请书中所示。公式I的化合物是有价值的药物活性化合物，适用于治疗和预防炎症性疾病，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞粘附和迁移的抑制剂和/或属于整合素组的粘附受体VLA-4的拮抗剂。它们通常适用于由白细胞粘附和/或白细胞迁移的不良程度引起或与之相关的疾病的治疗或预防，或者在其中基于VLA-4受体与其配体的相互作用的细胞-细胞或细胞-基质相互作用发挥作用。此外，本发明还涉及公式I化合物的制备方法，它们在上述疾病状态的治疗和预防中的应用以及含有公式I化合物的制药制剂。
• Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them
  申请人：——

  公开号：US20020143043A1

  公开（公告）日：2002-10-03

  Substituted imidazolidine derivatives of the formula I, 1 in which B, E, W, Y, R, R 2 , R 3 , R 30 , e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations which contain compounds of the formula I.

  公式I的取代咪唑啉衍生物，其中B、E、W、Y、R、R2、R3、R30、e和h具有所述权利要求中指示的含义。公式I的化合物是有价值的药物活性化合物，适用于治疗和预防炎症性疾病，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞黏附和迁移的抑制剂和/或属于整合素组的黏附受体VLA-4的拮抗剂。它们通常适用于治疗或预防由于白细胞黏附和/或白细胞迁移的不良程度引起的疾病或与之相关的疾病，或在其中基于VLA-4受体与其配体的相互作用的细胞-细胞或细胞-基质相互作用起作用。此外，本发明还涉及公式I化合物的制备方法，它们的用途，特别是作为药物活性化合物，以及含有公式I化合物的制药制剂。
• SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1183241A1

  公开（公告）日：2002-03-06
• US6331552B1
  申请人：——

  公开号：US6331552B1

  公开（公告）日：2001-12-18
• US6399643B1
  申请人：——

  公开号：US6399643B1

  公开（公告）日：2002-06-04